





CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

Gina N. Shishima

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David J. Grdina

Serial No.: 09/523,886

Filed: March 13, 2000

For: A METHOD FOR PROTECTION AGAINST TUMOR METASTASIS

FORMATION

Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: ARCD:318US/GNS

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Washington, D.C. 20231

Sir:

A corrected filing receipt is hereby requested in view of the error which appears in the original. For the convenience of the Patent and Trademark Office, attached is a photocopy of the original receipt on which the error has been noted in red.

There is an error in the Continuing Data; please add the following Continuing Data information -- Claims the benefit of priority from U.S. Provisional Application No. 60/125,605 filed 3/19/99 --.

connection with the filing of this document. However, should any fee under 37 CF.R. \$37.16 to

1654914.1

1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct said fee from Fulbright & Jaworski Deposit Account No.: 50-1212/10006736/GNS. In support of the requested correction, Applicant attach hereto a copy of the inventor's Declaration filed September 6, 2000.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima

Reg. No. 45,104

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspta.gov

FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS IND CLAIMS TOT CLAIMS APPLICATION NUMBER FILING DATE **GRP ART UNIT** 1614 P-01904US1 6 31 3 509 J 09/523.886 **J**03/13/2000

Fulbright & Jaworski LLP **Suite 2400** 600 Congress Avenue Austin, TX 78701



FILING RECEIPT

OC000000005403360°

Date Mailed: 09/15/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

✓ David J. Grdina, Naperville, IL; (Luka Milas, Houston, TX;

Continuing Data as Claimed by Applicant U.S. PROVISIONAL Application 10. 60/125/605 filed 3/19/99 Foreign Applications

If Required, Foreign Filing License Granted 05/09/2000

** SMALL ENTITY **

Title

V Method for protection against tumor metastasis formation

Preliminary Class

514

Data entry by: GUNTER RILEY, JOYCE

Team: OIPE

ARCD: 318US

FULBRIGHT S &

AUSTIN

OCT 1 3 2000

RECEIVED

IXI LLI



GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request to corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231